October 22-26, 2025
Hynes Convention Center
Boston, Massachusetts

Late-Breaking and Clinical Trial Abstract Submission Deadline: Wednesday, September 10, 2025, 1 p.m. ET (Opens Wednesday, August 27, 2025)

Scientific Committee Cochairs

Ryan B. Corcoran, Massachusetts General Hospital, Boston, Massachusetts (AACR)
Tim F. Greten, National Cancer Institute, Bethesda, Maryland (NCI) 
Elena Garralda, Vall d’Hebron Institute of Oncology, Barcelona, Spain (EORTC) 

Hosted by the American Association for Cancer Research, the National Cancer Institute, and the European Organisation for Research and Treatment of Cancer, the 2025 Molecular Targets and Cancer Therapeutics conference will once again attract 1,500-2,000 academics, scientists, regulatory agency staff, investors, and biotech and pharmaceutical industry representatives from across the globe to discuss innovations in drug development, target selection, the impact of new discoveries in cellular and molecular biology, and early clinical trials. 

Innovative, targeted therapeutics are discovered through the rapid advances in our understanding of the molecular basis of cancer. Continued clinical progress in cancer treatments is accomplished through the conduct of translational research projects, efficient new drug development, and the execution of large, prospective, randomized, multicenter cancer clinical trials. This requires a joint and global approach and exchange of information early in the development process.